The objective of this study was to measure lutein and zeaxanthin plasma levels after oral lutein administration in preterm infants. Lutein was given orally in a single dose of 0.5 mg/kg to 10 preterm infants at a mean age of 52 h of life. Plasma lutein and zeaxanthin were measured before and 6, 24, 48, and 120 h after lutein administration. All infants had detectable plasma levels of lutein and zeaxanthin before treatment. Lutein concentration increased by 13.5% at 6 h and by 16.7% at 24 h, and returned to the basal level at 120 h after treatment. Zeaxanthin remained unchanged during the study period. Lutein is well absorbed in preterm infants when given orally. The clinical impact of increasing plasma lutein concentrations on macular development and visual function needs further investigation.
Introduction
Lutein and zeaxanthin are two yellow carotenoids that are specifically located in the neuronal retina and are believed to have a role in protecting it against oxidative and light damage (Landrum and Bone, 2001) . As humans cannot synthesize lutein or zeaxanthin, human milk is the only dietary source for the neonate (Sommerburg et al., 2000) . There are only a few studies that report on the normal concentration of carotenoids in neonates. O'Brien and Hammond (1987) showed that levels of plasma carotene concentrations of infants from 0 to 6 months of age ranged from 0 to 0.75 mmol/l. Among infants o3 months of age plasma carotene concentration of breast-fed infants was 0.80 ± 0.43 mmol/l, whereas in formula-fed infants was 0.41±0.28 mmol/l (Leung et al., 1990) . The correlation observed between lutein in plasma of the mothers and in their breast-fed infants suggests that lutein is well absorbed in the neonatal gut (Jewell et al., 2001) . However, normal values of plasma lutein and zeaxanthin in full term and in preterm infants are unknown, and no data on the neonatal intestinal absorption of these micronutrients are available up to now.
This study was designed to evaluate intestinal absorption of lutein in preterm infants in the early neonatal period.
Materials and methods
Our study includes 10 preterm infants with mean (s.d.) birth weight of 1785 g (365) (range: 1340-2345 g) and mean gestational age of 32.6 (1.7) weeks (range: 30-35 weeks). Six infants were healthy preterm babies, three had a mild respiratory distress syndrome, and four infants were exposed to phototherapy. Enteral feeding was started at 1 h of life using preterm formula. Ethical Committee of Department approved the study and consent was obtained from parents. Lutein (LUTEINofta, NEOOX-SOOFT, Fermo, Italy) was given orally in a single dose of 0.5 mg/kg by a nasogastric tube, 30 min before the meal of 9 a.m.
Blood draws for lutein and zeaxanthin measurement were taken soon before the lutein administration and 6, 24, 48, and 120 h thereafter. Blood samples were collected into a light protected tube and were immediately centrifuged at 2000 r.p.m., 4 1C for 10 min, and aliquots of plasma were stored at À80 1C until analyzed with HPLC (Yeum et al., 1998) . Concentrations of lutein and zeaxanthin were calculated by the ChromQuest software using an external standard calibration curve. The total imprecision was o10% at low and high concentration for both metabolites.
Plasma cholesterol and triglycerides concentrations were also determined at time 0 and then at 48 and 120 h after lutein administration. Plasma triglyceride and total cholesterol contents were determined by enzymatic methods (kit Boehringer, Mannheim, Germany) on Olympus AU2700 analyzer (Olympus GmbH, Hamburg, Germany).
Results
Lutein was well tolerated and no gastrointestinal or feeding complications were observed during the study period. The study was started at mean (s.d.) age of 52 h (43) of life (range: 13-118 h). Figure 1 shows mean plasma concentrations of lutein and zeaxanthin. Basal mean (s.d.) plasma concentrations were 0.361 mmol/l (0.079) (range: 0.273-0.516) for lutein and 0.126 mmol/l (0.039) (range: 0.063-0.181) for zeaxanthin, suggesting placental transfer from mother to fetus. Mean plasma lutein increased in the first 24 h after oral administration, being the mean increase 13.5% after 6 h and 16.7% after 24 h. Thereafter, plasma lutein decreased to a mean value of 0.373 mmol/l (0.118) at 120 h after the treatment. All infants showed an increase of plasma lutein concentration after oral administration, reaching the maximum level after 6 h in four babies, after 24 h in three babies, and after 48 h in three infants. The increase of lutein concentration was independent from birth weight, postnatal age, and total dose of lutein administered.
Plasma zeaxanthin remained unchanged during the study period, reaching a mean value of 0.119 mmol/l (0.046) (range 0.029-0.158) 120 h after lutein administration. We failed to find a significant correlation between lutein and zeaxanthin concentrations at any study time.
Cholesterol and its fractions, and triglycerides were always in the normal range for newborn infants and did not change during the study period. There was no correlation between lutein concentrations and cholesterol or triglycerides levels during the study.
Discussion
Our experience shows that a dose of 0.5 mg/kg orally administered lutein is well absorbed by the premature gut, even in infants of low gestational age. In fact, all the studied infants reached the peak level at 6-24 h after the administration, and lutein concentrations returned to basal level at 120 h after lutein oral intake. Zeaxanthin levels did not change during the study period and were not influenced by lutein administration. It has been suggested that lutein and zeaxanthin can exist in an equilibrium involving the intermediate carotenoid 3
0 -epilutein, by direct isomerization or previous oxidation/reduction (Khachik et al., 1995) . It is possible that this equilibrium is not reached in the neonatal period because of a faster lutein clearance connected to the retinol formation or, alternatively, because zeaxanthin is rapidly fixed in the tissues.
To our knowledge this is the first study dealing with the neonatal absorption of lutein after a single-dose oral supplementation. Our data show that lutein is well absorbed in the preterm gut when orally administered, but the clinical significance of the increasing plasma lutein concentrations has to be clarified, with respect to the antioxidant efficacy and to the macular development and visual function. 
